Farrell Peter C
- SEC CIK
- 0001186102
In the past year, 8 open-market sale filings worth $5.01M and no purchases.
Current role at each company
- RMD Resmed IncDirectoras of Sep 4, 2026
- ARCT Arcturus Therapeutics Holdings Inc.Directoras of Jun 15, 2026
- EOLS Evolus, Inc.Directoras of Jan 31, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $5.01M
- 8 filings
- Net
- −$5.01M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Farrell Peter C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
RMD Resmed Inc
Director21 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 (view filing)6:30 AM ET | Sep 2 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −970 | $234.73 | −$227.7K | −1.8%51.8K after | 10b5-1 |
| Aug 6, 2026 (view filing)2:29 PM ET | Aug 5 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −8.00K | $225.00 | −$1.80M | −13.2%52.8K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $225.00 | −$450.0K | −3.2%60.8K after | 10b5-1 |
| Mar 5, 2026 (view filing) | Mar 4 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $260.22 | −$520.4K | −3.1%62.8K after | 10b5-1 |
| Feb 6, 2026 (view filing) | Feb 4 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $251.31 | −$502.6K | −3.0%64.8K after | 10b5-1 |
| Jan 9, 2026 (view filing) | Jan 7 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $248.83 | −$497.7K | −2.9%66.8K after | 10b5-1 |
| Dec 4, 2025 (view filing) | Dec 3 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $251.47 | −$502.9K | −2.8%68.8K after | 10b5-1 |
| Nov 13, 2025 (view filing) | Nov 12 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $252.05 | −$504.1K | −2.9%66.1K after | 10b5-1 |
| Jul 3, 2025 (view filing) | Jul 2 | 1 day | Farrell Peter CDirector | SSaleResMed Common Stock | −945 | $255.49 | −$241.4K | −1.4%68.3K after | 10b5-1 |
| Jun 6, 2025 (view filing) | Jun 4 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −2.00K | $247.32 | −$494.6K | −2.8%69.2K after | 10b5-1 |
EOLS Evolus, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 (view filing) | Sep 6 | Same day | Farrell Peter CDirector | PPurchase | +10.0K | $9.10 | +$91.0K | New position10.0K after |